AbbVie has reached a three-year agreement with the Trump administration to reduce drug costs and expand U.S. investment in pharmaceutical development.
Under the deal, AbbVie will provide lower prices through Medicaid and direct-to-patient TrumpRx programs for several popular therapies, including Humira, Alphagan, Combigan and Synthroid, according to a Jan. 12 news release. The company also pledged $100 billion over 10 years in U.S.-based research, development and capital investments.
The agreement exempts AbbVie from tariffs and future federal pricing mandates. AbbVie joins at least 13 other manufacturers that have signed similar deals with the administration. In December, the White House announced “most-favored-nation” pricing agreements with nine major drugmakers, including GSK, Merck and Sanofi, for products across cancer, diabetes, HIV and asthma. Earlier deals included Pfizer, Eli Lilly and Novo Nordisk.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.